Tenax Therapeutics (Formerly Known As Oxygen Biotherapeutics, Inc.)
3189 Airway Avenue, Building C
Costa Mesa
California
92626
United States
Tel: 800-809-6054
Fax: 714-427-6361
Website: http://www.oxybiomed.com/
298 articles about Tenax Therapeutics (Formerly Known As Oxygen Biotherapeutics, Inc.)
-
Tenax Therapeutics to Present at the 36th Annual Roth Conference
3/12/2024
Tenax Therapeutics, Inc. today announced that it will participate in the 36th Annual Roth Conference in Dana Point, California, from March 17-19, 2024.
-
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
2/29/2024
Tenax Therapeutics, Inc. today announced Dr. Sanjiv Shah will present data and review the scientific basis for the use of levosimendan in PH-HFpEF.
-
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
2/20/2024
Tenax Therapeutics, Inc. today announced it has secured global development, commercial, and IP rights to oral and subcutaneous levosimendan for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).
-
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
2/8/2024
Tenax Therapeutics, Inc. announced that the first patient has enrolled in the Company’s Phase 3 LEVEL Study.
-
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
2/8/2024
Tenax Therapeutics, Inc. announced the pricing of a public offering of 1,600,000 shares of its common stock and warrants to purchase up to 3,200,000 shares of its common stock at a purchase price of $5.65 per share and associated Common Warrant.
-
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application
2/6/2024
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has allowed its patent application with claims covering the use of TNX-103 (oral levosimendan).
-
Tenax Therapeutics Announces Reverse Stock Split - December 29, 2023
12/29/2023
Tenax Therapeutics, Inc. announced that it will be executing a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-80.
-
Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board
11/17/2023
Tenax Therapeutics, Inc. announced the appointment of Javed Butler, M.D., M.P.H, M.B.A., to the Company’s PH-HFpEF Scientific Advisory Board.
-
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023
11/13/2023
Tenax Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has reviewed and cleared the Company’s Investigational New Drug (IND) Application for TNX-103 (oral levosimendan) for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF), enabling Tenax to proceed with the first of two Phase 3 studies.
-
Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
7/19/2023
Tenax Therapeutics, Inc. announced today that the United States Patent and Trademark Office (USPTO) has granted a new method of use patent for oral levosimendan (TNX-103) in the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF), expiring in 2040.
-
Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
5/31/2023
Tenax Therapeutics, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application with claims covering the use of TNX-103.
-
Tenax Therapeutics Provides 2023 Business Update
4/12/2023
Tenax Therapeutics, Inc. (Nasdaq: TENX) today provided a business update outlining the Company’s product development plans for 2023.
-
Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
3/22/2023
Tenax Therapeutics, Inc. announced today that the Company has been issued a patent by the United States Patent and Trademark Office (USPTO) with claims covering the use of IV levosimendan in the treatment of pulmonary hypertension associated with HFpEF.
-
Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering
2/3/2023
Tenax Therapeutics, Inc. announced today the pricing of a public offering of (i) 8,666,666 shares of its common stock (or pre-funded warrants in lieu thereof) and (ii) warrants to purchase up to 17,333,332 shares of its common stock.
-
Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)
2/1/2023
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application with claims covering the use of IV levosimendan in the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).
-
Tenax Therapeutics Announces Reverse Stock Split - Jan 04, 2023
1/4/2023
Tenax Therapeutics, Inc. announced that it will be executing a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20.
-
SIFI, BeiGene and Novo Holdings shared promising updates on their proposed treatments for acanthamoeba keratitis, relapsed or refractory CCL and myasthenia gravis.
-
Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
10/10/2022
Tenax Therapeutics, Inc. announces the presentation of positive data from a study of PH-HFpEF patients being treated with oral levosimendan.
-
Tenax Therapeutics Announces the Evaluation of Strategic Alternatives
9/15/2022
Tenax Therapeutics, Inc. today announced that the Company is evaluating alternative strategic paths focused on maximizing shareholder value.
-
Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH)
5/25/2022
Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will host a key opinion leader (KOL) webinar about TNX-201.